Background. The National Comprehensive Cancer Network (NCCN) has instituted treatment guidelines for stage 2A and stages 2B and 3 extremity and superficial trunk soft tissue sarcomas (ETSTS). This study examined adherence to the NCCN guidelines and factors associated with nonadherent treatment and survival outcomes. Methods. Patients with stage 2A and stages 2B and 3 ETSTS (n = 15,957) were categorized as undergoing adherent or nonadherent treatment based on the 2014 NCCN guidelines. Multivariate logistic regression models were used to determine factors associated with nonadherent treatment. Overall survival (OS) and disease-specific survival (DSS) were calculated, and Cox models were used to generate adjusted survival curves and hazard ratios (HRs). Results. The findings showed that 87.2% of the patients with stage 2A disease and 58.3% of the patients with stage 2B or 3 disease received adherent treatment. Community treatment facilities and uninsured or unknown insurance status were associated with nonadherent treatment for both stage groups. Adherent treatment was associated with higher 5-year adjusted OS and DSS for stage 2A and stage 2B or 3 patients. In Cox models, nonadherent treatment was associated with worse survival for both stage 2A disease (HR, 2.31; 95% confidence interval [CI], 2.02-2.63) and stages 2B and 3 disease (HR, 1.63; 95% CI, 1.53-1.73). Increasing age and non-private insurance were associated with poorer outcomes. For stages 2B and 3 disease, treatment at a community center and African American race were associated with worse survival. Conclusions. Adherence to NCCN guidelines is excellent for stage 2A and poor for stages 2B and 3 ETSTS. Adherent treatment was associated with improved survival outcomes, highlighting the importance of adherence to NCCN guidelines.
Consensus-based treatment guidelines were developed by the National Comprehensive Cancer Network (NCCN) to provide guidance for delivery of high-quality, standardized treatment for extremity and superficial trunk soft tissue sarcoma (ETSTS). 1 Although the guidelines appear ambiguous regarding the sequence and necessity of all therapeutic methods, a minimum threshold of treatment remains for patients with high-grade tumors no larger than 5 cm (stage 2A) and those with high-grade tumors larger than 5 cm (stages 2B and 3). 2 According to the NCCN guidelines, adherent treatment for stage 2A disease is either R0 (microscopically negative) resection alone or surgical resection plus radiation therapy (RT). Adherent treatment for patients with stage 2B or 3 disease is defined as surgical resection and RT, with or without chemotherapy.
Previous studies evaluating RT use for stages 2 and 3 extremity sarcoma demonstrated wide variability in administration based on geographic region, age and sex. [3] [4] [5] [6] [7] A recent study by Sherman et al. 8 found that 65% of patients with stage 3 disease were treated with surgery and RT, indicating a discrepancy between consensus recommendations and RT use. However, treatment for stages 2 and 3 disease was not stratified by stage 2A and stages 2B or 3, as in the NCCN guidelines, making it difficult to ascertain the true percentage of patients receiving guideline-adherent therapy and, by extension, what risk factors were associated with nonadherent treatment.
Recently, the association between survival and adherence to NCCN guidelines has been demonstrated for multiple cancer types, including colon, 9 esophageal, 10 and ovarian 11 cancer. However, the impact of adherence to NCCN guidelines for patients with ETSTS is unknown.
In the current study, we assessed treatment adherence to the NCCN guidelines and risk factors for receiving nonadherent treatment of patients with stage 2A and those with stage 2B or 3 ETSTS to assess treatment quality nationally using data from National Cancer Database (NCDB). In addition, we evaluated the impact of adherence to NCCN guidelines on stage-specific survival outcomes. We hypothesized that patients receiving guideline-adherent treatment would have a higher 5-year OS and a lower risk of death than those receiving nonadherent treatment.
MATERIALS AND METHODS

Data Source
The NCDB is a prospective, hospital-based cancer registry sponsored by the American College of Surgeons and the American Cancer Society. 12 It captures approximately 70% of all new cancer cases in the United States and includes clinicopathologic, treatment, and outcome variables. 13 Because the data are de-identified, this study was considered exempt by The University of Texas MD Anderson Cancer Center Institutional Review Board.
Analytic Cohort
Patients with a diagnosis of ETSTS (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) were identified from the NCDB Sarcoma Participant Use File (n = 99,876) using the International Classification of Diseases for Oncology (3rd ed) topography codes C471, C472, C476, C491, C492, and C496 (Supplementary Table 1 ). All histologic subtypes included in the data were individually vetted to exclude non-sarcomatous or mixed histologies. The following subgroups also were excluded: pediatric patients, central nervous system tumors, osteosarcomas, patients not treated at the reporting hospital, stages 1 and 4 disease, and patients with incomplete information (Supplementary Fig. 1 ). The remaining patients were grouped into stage 2A and stages 2B and 3 according to the American Joint Committee on Cancer (AJCC) (7th ed) soft tissue sarcoma staging guidelines. 2 The definition of adherence was based on the NCCN treatment recommendations for ETSTS.
1 ''Adherent'' patients with stage 2A disease must have received marginnegative (R0) surgery alone or surgery with any margin status plus radiation therapy (either pre-or postoperatively). Patients with stage 2B or 3 disease must have undergone surgical resection and radiation therapy with or without chemotherapy ( Supplementary Fig. 2 ).
Variables
In addition to the demographic and clinical data provided in the NCDB, Charlson comorbidity scores, insurance status, geographic region of the treatment facility, travel distance from the patient's ZIP code area to the treatment facility, and type of treatment facility (academic, comprehensive, or community) were examined. Insurance status was categorized as private, government plan (Medicare, Medicaid, or other government policy), or uninsured/unknown. Additionally, treatment facility location was re-categorized as Northeast, Midwest, South, or West from the nine regional designations used in the NCDB.
Statistical Analyses
A multivariable logistic regression model was constructed to determine independent risk factors associated with receiving nonadherent treatment. Stepwise selection was used for model building. Covariates deemed essential to clinical outcomes, such as age and gender, were forced into the model. Odds ratios and 95% confidence intervals (CIs) were calculated, and forest plots were generated.
Survival analyses for the adherent versus nonadherent treatment groups were conducted using three distinct statistical methods. The Kaplan-Meier estimator was used to calculate unadjusted OS curves.
Disease-specific survival was estimated using relative survival, as previously described. 9, 14 In brief, relative survival was determined using the Kaplan-Meier method by calculating the ratio of observed survival in the analytic cohort to expected survival of a comparable sex-and agematched population, obtained from the Human Mortality Database. 15 Adjusted survival curves also were estimated from Cox regression models. The models were used to estimate hazard ratios (HRs) and 95% CIs for factors associated with increased risk of death. These three distinct statistical techniques provided a range of outcomes (similar to a sensitivity analysis) to confirm the robustness of the survival estimates for adherent and nonadherent groups. A p value lower than 0.05 was considered statistically significant. For all the analyses, SAS version 9.4 was used.
RESULTS
Patient Characteristics
In the final analytic cohort, 5734 patients had stage 2A disease and 10,223 had stage 2B or 3 disease. Demographic, disease, and treatment data are summarized in Supplementary Table 2 . Surgery was performed for 97.2% of the patients with stage 2A disease and for 91.3% of the patients with stage 2B or 3 disease. Few patients with stage 3 disease had positive nodal disease (2.1%), and 8% underwent amputation.
Adherent and Nonadherent Treatment
Among the patients with stage 2A disease, 5002 (87.2%) received adherent treatment ( Supplementary Fig. 2 ). Most of the patients receiving nonadherent treatment underwent inadequate surgical treatment.
Only 58.3% (n = 5960) of the patients with stage 2B or 3 disease received the appropriate regimen. Nearly twothirds of all nonadherent treatment patients with stage 2B or 3 disease had surgery alone. Few patients in the nonadherent treatment group received no treatment (2.4%).
Factors Associated with Nonadherent Treatment
A logistic regression model was used to investigate factors associated with receiving nonadherent treatment ( Fig. 1 ). In the multivariate analysis, a Charlson score of 2 or higher and uninsured/unknown insurance status were significantly associated with nonadherent treatment for both stage groups (p \ 0.05). The patients treated at a community facility for 2A disease were less likely to receive adherent treatment (Fig. 1a) , and the patients treated at comprehensive cancer centers for stage 2B or 3 disease were less likely to receive adherent treatment compared with those treated at an academic facility (Fig. 1b) .
The patients with stage 2A disease who lived more than 50 miles from the treatment facility were more likely to receive adherent treatment, whereas the patients with stage 2B or 3 disease and those who lived farther away ([20 miles) were more likely to receive nonadherent treatment. Female patients, Hispanic patients, and those with government insurance or a Charlson comorbidity score higher than 0 who had stage 2B or 3 disease also were more likely to receive nonadherent treatment.
Survival Analyses
The median follow-up period for the entire cohort was 3.18 years. The 5-year unadjusted OS for all the patients was 61.7%. The patients receiving adherent treatment had longer survival regardless of stage (p \ 0.01; Fig. 2a) . Adherence to the NCCN guidelines was associated with a 19.7% improvement in 5-year OS for stage 2A disease (78.4% vs 58.7%) and a 14.1% improvement in 5-year OS (59.7% vs 45.6%) for stage 2B or 3 disease (p \ 0.01).
The relative survival curves (representative of diseasespecific survival) are shown in Fig. 2b . Similar to the unadjusted OS, the 5-year relative survival rate was lower (p \ 0.01) for the patients receiving nonadherent treatment for both stage 2A disease (89.3% vs. 67.9%) and stages 2B and 3 disease (68.1% vs 52.6%).
After adjusting for significant covariates, we found that for the patients who had adherent treatment, the 5-year OS was 17.9% better for stage 2A disease (83.1% vs 65.2%) and 16.3% better for stages 2B and 3 disease (60.9% vs 44.6%) (Fig. 3a, b) . The adjusted OS curves stratified by individual treatment regimens are shown in Fig. 4 . Adherent regimens were associated with improved survival.
Adjusted HRs for mortality are shown in Table 1 . For stage 2A disease, a twofold increased mortality risk (HR, 2.31; 95% CI, 2.02-2.63) was found for those receiving nonadherent treatment. For stages 2B and 3 disease, we found a 63% increased mortality risk (HR, 1.63; 95% CI, 1.53-1.73) for those receiving nonadherent treatment. For both stage groups, non-private insurance was associated with significantly worse survival outcomes compared with private insurance.
DISCUSSION
This analysis of treatment adherence to NCCN guidelines showed both encouraging and worrisome patterns of treatment for ETSTS nationally. Our data showed that for stage 2A soft tissue sarcoma, treatment adherence was good, with 87.2% of the patients who had stage 2A disease receiving adherent treatment. However, the overall treatment adherence for stages 2B and 3 disease was poor, with only 58.3% of the patients receiving adherent treatment, largely because their treatment lacked RT. The patients treated at community facilities with increasing comorbidities and the uninsured patients were more likely not to receive adherent therapy. Treatment adherent to NCCN guidelines was associated with a 5-year OS increase of 16, 17 and even within disease types depending on stage (e.g., colon cancer ranges from 36 to 96%). 18 The adherence to RT reported in prior studies of ETSTS for stages 2 and 3 disease ranged from about 60-80% for the patients who underwent surgery. [4] [5] [6] [7] [8] However, treatment adherence to RT does not fully describe adherence to NCCN guidelines. The guidelines separate stage 2A and stages 2B and 3 disease with distinct treatment algorithms by stage group. We found that for stage 2A disease, when margin-negative resection is considered adherent treatment, treatment adherence was much better than shown in previous reports, approaching 90%.
Several potential explanations exist for the high nonadherence rates for stages 2B and 3 disease. First, RT is not necessary for patients who had amputation performed with an adequate margin, which represented 8% of stages 2B and 3 patients.
Second, stage definitions have evolved during the past decade. In 2010, the seventh edition of the AJCC staging system was published, and substantial changes were made to soft tissue sarcoma staging. In previous editions, lymph node involvement (N1 disease) was considered stage 4 disease. In the seventh edition, N1 disease was downgraded to stage 3, with lymph node dissection offered as a surgical treatment for nodal disease, together with surgery and RT to the primary tumor site. Previously, node-positive disease would have been considered stage 4 disease (and thus excluded from our analysis), and the treatment algorithm would have included chemotherapy. However, only 2.1% of the patients in our cohort with stage 2B or 3 disease were found to have node-positive disease.
In summary, even if we assumed that patients who underwent amputation did receive adherent treatment and excluded patients with node-positive disease, adherence would increase only to approximately 67%. Therefore, nodal status and the change in stage definitions over time, although factors to consider, do not account for most cases of nonadherence in stage 2B or 3 ETSTS. Progression to stage 4 disease is the most likely explanation for the 6.3% of the patients with stage 2B or 3 disease who underwent nonsurgical treatment, but we were unable to validate our hypothesis with the available data. Similarly, it is possible that some patients who underwent surgical resection without RT had development of distant metastases before the initiation of RT. However, in the randomized trial of pre-versus postoperative RT for patients with soft tissue sarcoma, 19 only 5 (5.2%) of the 96 patients had development of distant metastases before the initiation of postoperative RT. Thus, it is an unlikely explanation for the 2722 patients (33%) who had stage 2B or 3 disease treated with surgery alone or surgery plus chemotherapy.
A radical decrease in the number of patients with stage 2B or 3 disease with poor tumor biology who progress to the development of nonoperative disease may not be possible, but it should be feasible to increase substantially the number of patients with stage 2B or 3 disease who receive neoadjuvant or adjuvant RT together with surgery. Our data suggest that if all patients with stage 2B or 3 disease who undergo surgery were to receive RT, the treatment adherence would rise from 58 to 91.3%, approximating the adherence for stage 2A disease.
Currently, no data show the impact of adherence to NCCN guideline-recommended therapy on survival. The use of RT together with margin-negative surgical resection is well established as the standard of care. 20, 21 However, the impact of surgery and RT on survival outcomes has been largely debated. 20, 21 In the current study, treatment of stage 2B or 3 disease with RT was associated with approximately 12% improvement in 5-year OS. At least four studies analyzing Surveillance, Epidemiology, and End Results (SEER) data have reported an OS benefit for patients with high-grade or advanced-stage sarcoma receiving RT. 3, 6, 7, 22 An additional report from the NCDB supports the link between RT and survival. 5 Internationally, registry data from 922 patients in Denmark also showed an association of RT, with approximately 5% improvement in disease-specific survival. 23 If all stages 2B and 3 patients in our study would have received appropriate surgical resection and RT, extrapolation of our results suggests that the 5-year OS would have increased from about 45% to approximately 60%.
Independent of adherence to NCCN guideline-recommended treatment, for the patients with stage 2B or 3 disease, treatment at community facilities was associated with a 26% increased risk of death compared with treatment at academic facilities. More research is needed to determine which factors are affecting treatment adherence and subsequent mortality for these patients. 24 Although the uninsured group was small, we did note a statistically significantly increased risk of death, consistent with previous studies. 5 The strengths of the current study included the large sample with detailed pathologic data available for stratification of patients according into sarcoma-specific substages for which treatment recommendations are defined. Patients who did not receive surgery also were included for comparison.
This retrospective observational database study has some inherent limitations. For cases in which surgical resection would lead to adverse functional outcomes, EXTSARC-4 of the NCCN guidelines allow for nonsurgical treatment. 1 Potentially, then, some of those classified as nonadherent actually received adherent treatment if the intent of the nonsurgical therapy was to preserve functional outcome. However, only 1.7% of the patients with stage 2A disease and only 6.3% of the patients with stage 2B or 3 disease received nonsurgical treatment. Therefore, the number of patients who underwent nonsurgical treatment was relatively small and would not explain the large deficit in adherence seen for stages 2B and 3 disease. Additionally, registry data are subject to error during the abstraction and coding process. Other unmeasured confounders may remain that are not included in the model, leading to residual confounding. 25 Another potential limitation was that only the principal surgical event is coded into the NCDB. Therefore, those with positive margins during the primary surgery may have had re-excisions that were not included in the database. As a result, there may be some misclassification with respect to margin status. Very few patients in the analytic cohort were uninsured, and they may not be representative of the 16% of adults younger than 65 years who remain uninsured nationally. 26 Similarly, minorities were proportionally less than in the general U.S. population.
CONCLUSION
The treatment patterns of patients with stage 2 or 3 ETSTS vary considerably, and the current study provides an overall snapshot of adherence to NCCN guidelines. 
